Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

dc.contributor.author	Heyne, Nils
dc.date.accessioned	2021-11-15T10:14:17Z
dc.date.available	2021-11-15T10:14:17Z
dc.date.issued	2021
dc.identifier.issn	2468-0249
dc.identifier.uri	http://hdl.handle.net/10900/120762
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.ekir.2021.03.884	de_DE
dc.subject.ddc	610	de_DE
dc.title	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults	de_DE
dc.type	Article	de_DE
utue.quellen.id	20210824232002_00930
utue.publikation.seiten	1603-1613	de_DE
utue.personen.roh	Barbour, Thomas
utue.personen.roh	Scully, Marie
utue.personen.roh	Ariceta, Gema
utue.personen.roh	Cataland, Spero
utue.personen.roh	Garlo, Katherine
utue.personen.roh	Heyne, Nils
utue.personen.roh	Luque, Yosu
utue.personen.roh	Menne, Jan
utue.personen.roh	Miyakawa, Yoshitaka
utue.personen.roh	Yoon, Sung-Soo
utue.personen.roh	Kavanagh, David
dcterms.isPartOf.ZSTitelID	Kidney International Reports	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	6	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE

Files in this item

Files	Size	Format	View
There are no files associated with this item.